

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **December 3, 2024**

**PROPANC BIOPHARMA, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of Incorporation)

**000-54878**

(Commission  
File Number)

**33-0662986**

(IRS Employer  
Identification Number)

**302, 6 Butler Street**

**Camberwell, VIC, 3124 Australia**

(Address of registrant's principal executive office) (Zip code)

**+61-03-9882-0780**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01 Entry into a Material Definitive Agreement.**

Effective December 3, 2024, Propanc Biopharma, Inc. (the "Company") entered into and closed a loan agreement (the "Loan") with Aggro Investments Pty Ltd (the "Investor"), pursuant to which the Investor loaned the Company an aggregate principal amount of \$175,000 AUD. The Company intends to use the net proceeds therefrom for repayment of existing debt, payment of certain regulatory expenses and general working capital purposes.

The term of the Loan is four months or less (to be determined at the discretion of the Company), with \$70,000 AUD due on February 28, 2024 and \$105,000 AUD due on April 2, 2024. Interest in the amount of 12% per annum is due monthly in arrears.

The Investor also loaned the Company \$15,000 to be used for general working capital purposes between November 13, 2024 and December 3, 2024.

**Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The applicable information set forth in Item 1.01 of this Form 8-K with respect to the Loan above is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

Exhibit No.	Description
4.1	<a href="#">Loan Agreement with Aggro Investments Pty Ltd dated December 3, 2024.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 6, 2024

**PROPANC BIOPHARMA, INC.**

By: /s/ James Nathanielsz

Name: James Nathanielsz

Title: Chief Executive Officer and Chief Financial Officer

---



**To:** Mr. Josef Zelinger  
**CC:** Dr. Julian Kenyon  
**From:** Mr. James Nathanielsz

**Subject:** Loan to Propanc Biopharma Inc. - Aggro Investments Pty Ltd

Dear Josef Zelinger,

The Board of Directors at Propane Biopharma Inc. ("Propanc") confirm acceptance and receipt of funds for the sum of one hundred and seventy-five thousand Australian dollars (AUD 175,000) from Aggro Investments Pty Ltd (the "lender") of 59 Seymour Road, Elsternwick, Vic 3185 ("address").

The loan to Propanc is subject to the following terms & conditions:

- **Amount:** A\$175,000.00
- **Term:** 4 months or less at the discretion of Propanc (the borrower)
- **Commencement date:** 03 December 2024
- **Interest rate:** 12% pa payable monthly in arrears (default rate is 18% pa)
- **Repayment:** 28 February, 2025, minimum of A\$70,000.00, 2 April, 2025, balance of A\$105,000.00

Sincerely,

A handwritten signature in black ink, appearing to read 'J. Nathanielsz', written over a horizontal line.

James Nathanielsz  
Chief Executive Officer

Approved by,

A handwritten signature in black ink, appearing to read 'Julian Kenyon', written over a horizontal line.

Dr Julian Kenyon  
Director

Approved by,

A handwritten signature in black ink, appearing to read 'Josef Zelinger', written over a horizontal line.

Josef Zelinger  
Aggro Investments Pty Ltd